Skip to content

Neuroplasticity: all studies

Page 178 of 178: studies 1,771 to 1,773 of 1,773, newest first. Back to the neuroplasticity overview

Research

Mindfulness-Based Psilocybin-Assisted Therapy (MB-PAT) for cancer-related demoralization in Canada: the case for a hybrid group-based delivery model

Christopher P. Albertyn, Jérémie Richard, Ron Joseph Shore et al. preprint

Demoralization syndrome (DS) - a distinct clinical entity characterized by helplessness, hopelessness, and a persistent loss of meaning - affects approximately one in five Canadians with advanced cancer and is associated with increased desire for hastened death, negative clinical outcomes, and higher economic burden, yet recognition and treatment of DS remains suboptimal in modern oncology....

Case series of psilocybin self-medication for spinal cord injury

SSRN Electronic Journal Robin Sandell, Adele Lafrance, Olivia Gosseries et al. preprint

Current spinal cord injury treatments primarily manage symptoms rather than promote neurological recovery. Psilocybin enhances neuroplasticity through 5-HT2A agonism and brain-derived neurotrophic factor upregulation, suggesting therapeutic potential for spinal cord injury rehabilitation. We conducted semi-structured interviews with three individuals who had incomplete spinal cord injuries...

Esketamine-induced dentate gyrus plasticity in treatment resistant depression: First-in-human evidence

Research Square Alice Le Berre preprint

Abstract Background: Treatment-resistant depression (TRD) involves impaired hippocampal plasticity. Preclinical work showed synaptic potentiation and dendritic spine growth in the dentate gyrus (DG) after esketamine (ESK), but human evidence is lacking. We aimed to detect early DG changes after ESK using advanced diffusion MRI, and to test whether baseline MRI metrics predict clinical response....